REFERENCES

Aarabi, B.; Haghshenas, M. and Rakeii, V. (1998): Visual failure caused by suprasellar extramedullary hematopoiesis in beta thalassemia: case report. Neurosurgery, 42(4): 922-5.

Abd El-Razek, A.A. (1990): Chelation of iron overload in pediatrics. M. D. Thesis in Pediatric, Ain Shams University 108 – 109.

Abd, E.L. Kader J. (2001): School performance in children liver disease. MSC. Thesis in pediatrics Benha faculty of Medicine. 62-63.

Abdollah, S.; Bekheirn, R.; Kamgar, M. and Pourzahedgilani, N. (2003): Metabolic and endocrinolgical complications in β thalassemia. 3(1): 4.

Abu El-Yazyd, M.D. (2004): Visual and auditory assessment in Egyptian thalassemic children with long term use of desferrioxamine. M.S.C. Thesis in pediatrics Tanta Faculty of Medicine 70: 75.

Adamkiewicz, T.V.; Berkovitch, M.; Krishnan, C.; Polsinelli, C.; Kermack, D. and Olivieri, N.F. (1998): Infection due to Yersinia enterocolitic in a series of patients with beta-thalassemia: incidence and predisposing factors. Clin. Infect. Dis., 27(6): 136-6.

Aessopos, A.; Farmkis, D. and Karagiorga, M. et al. (2001): Cardiac involvement in thalassemia intermedia a multicenter study. Blood, 97: 3411-3418.

Albera, R.; Pia, F.; Morra, B.; Lacilla, M.; Bianco, L.; Gabutti, V. and Piga, A. (1988): Hearing loss and desferrioxamine in homozygous beta-thalassemia. Audiology, 27(4): 207-14.

Albera, R.; Pia, F.; Morra, B.; Lacilla, M.; Bianco,, A.; El-Shanti, H. and Abuekteish, F. (1999): Effect of desferrioxamine in acute hemolytic anemia of glucose-6-phosphate dehydrogenase deficiency. Acta. Hematol., 101(3): 145-8.

Aldudak, B.; Karabay Bayazit, A.; Noyan, A.; Ozel, A.; Anarat, A.; Sasmaz, I.; Kiline, Y.; Gali, E.; Anarat, R. and Dikmen, N.

(2000): Renal function in pediatric patients with beta-thalassemia major. Pediatr. Nephrol., 15(1-2): 109-112.

Aliberti, B.; Patrikiou, A.; Terentiou, A.; Frangatou, S. and Papadimitriau, A. (2001): Spinal cord compression due to extramedullary hematopoiesis in patients with thalassemia. Journal of Neurology, 248(1): 18-22.

Alp, M. Cohen, A.; Eleftheriou, A.; Piga, A. and Porter, J. (2001): Endocrine Complications in thalassaemia major in: Guidelines for the Clinical Management of thalassaemia. TIF: 4 – 49.

Al-Salem, A.H. (1999): Is splenectomy for massive splenomegaly safe in children? Am. J. Surg., 178(1): 42-5.

Ambrosetti U, Donde E, Piatti G and Cappellini MD (2000): Audiological evaluation in adult beta-thalassemia major patients under regular chelation treatment. Pharmacol Res 42: 485-487.

Angelucci, E.; Brittenham, G.; Mclaren, C.; Ripalti, M.; Baronceani, D.; Giardini, C.; Galimberti, M.; Polchi, P. and Lucarelli, G. (2000): Hepatic iron concentration and total body iron stores in thalassemia major. New England J. Med., 343(5): 327-331.

Anie, K.A. and Massaglia, P. (2001): Psycological therapies for thalassemia: Cochran Database syst. Rev., 1(3): CD002890.

Argiolu F, Diana G, Avignone A, Cao A and Di Ninni S (1991): Hearing impairment during desferrioxamine therapy for thalassemia major. J Pediatr 118: 826-827.

Atikin, K. and Ahmed, W.I. (2001): Young people coping with thalassemia major or sickle cell disorder. Soc. Sci. Med., 53(5): 615-25.

Aydin, B.; Yaprak, I.; Akarsn, D.; Okten, N. and Ulgen, M. (2003): Psychological aspects and psychiatric disorders in children with thalassemia major. Syst. Rev.

Aydinok, Y.; Dacran, S.; Polat, A.; Kavakli, N.; Nigli, G.; Coker, M.; Kanter, M. and Centigul, N. (2002): Endocrine

complications of patients with B-thalassemia major. J. Trop. Ped., 48: 50-54.

Bacon, B.R.; Tavill, A.S.; Brittenham, G.M.; Park, C.H. and Recknagel, R.O. (1983): Hepatic lipid peroxidation in vivo in rats with chronic iron overload. J. Clin. Invest., 71: 429-33.

Barkovitch, M.; Bistritzer, T.; Milone, S.D.; Perlman, K.; Kuchacrczyk, W.; Koner, G. and Oliveri, N.F. (2000): Iron deposition, in the anterior pituitary in the homozygous beta thalassemia. J. Pediatr. Endocrinol. Metabl., 13(2): 179-84.

Baysal, E. and Carver, M.F.H. (1995): The B and δ thalassemia repository. Hemoglobin, 19: 213-236.

Behrman, R.E.; Kliegman, R.M. and Jenson, H.B. (2004): Hemolytic anemias. In Nelson Textbook of Pediatrics, 17th ed. Behrman RE, Gliegman RM, Nelson WE and Vaughan VC (eds) Saunders Co. Philadelphia, London, Toronto, 1245: 56.

Bensinger, W.; Martin, J.; Storer, B.; Clift, R.; Forman, S.J.; Negrin, R.; Kashyap, A.; Flowers, M.; Lilleby, R.N.; Chauncey, T.R.; Storb, R. and Appelbaum, F. (2001): Transplantation of bone marrow as compared with peripheral blood cells from HLA-identical relatives in patients with hematologic cancer. N. Engl. J. Med., 344(3): 175-181.

Benz , T.andGiardina,M(1995):Fertility in thalassemia major Eur. J. Haematol; 52 (1): 29 – 33.

Beratis S (1993): Psychosocial status in pre-adolescent children with β-thalassaemia. Journal of Psychosomatic Research; 37: 271-9.

Bergeron, R.J.; Wiegand, J. and Brittenham, G.M. (2002): HBED ligand: preclinical studies of a potential alternative to deferoxamine for treatment of chronic iron overload and acute iron poisoning. Blood; 99(8): 3019-26.

Bloch RS (1990): Hematologic disorders. In: Duane TD, ed. Clinical Ophthalmology. Philadelphia: JB Lippincott Co. 5(23): 1-11.

Bloomfield, S.E.; Markenson, A.L.; Miller, D.R. and Peterson, C.M. (1978): Lens opacities in thalassemia. J. Pediatr Ophthalmol bismStraus; 15 (3): 154 – 6.

Bonetti, M.G.; Cashivta, Scanderbery, A.; Criconia, G.M. and Mazza, P. (1996): Hepatic iron overload in thalassemic patients: proposal and validation of an MRI method of assessment. Pediatr. Radiol., 26(9): 650-6.

Bournerias, F.; Monnier, N.; Dufier, J.L. and Reveillaud, R.J. (1987): Severe ocular toxicity of desferrioxamine in the hemodilayzed patient. Neprhologie; 8(1): 27-9.

Brittenham, G.M.; Griffith, P.M. and Nienhuis, A.W. et al. (1994): Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N. Engl. J. Med., 331: 567-73.

Brittenham, G.M.; Taylor, C.M.; Angelucci, E. and Olivieri, N.F.; (1998): Long-term evaluation of the efficiency of iron chelation in thalassemia major with balance studies using hepatic iron concentration to determine body iron stores. Blood. 1998; 82 (1) : 38b.

Brownlee, B.; (1999): Inside the teen Brain, U.S. News & World Report, August 9.

Canaton,E; Akar,D.(1995):Osteoporosis and bony fractures in thalassemia Acta. Hematol., 61(4):111-115

Cantineaux, B.; Hariga, C.; Ferster, A.; De Maertelaere, E.; Toppet, M. and Fondu, P. (1987): Neutrophil dysfunctions in thalassemia major: The role of cell iron overload. Eur. J. Haematol; 39 (1): 28 – 34.

Cantinieau, R.; Hariga, C.; Ferster, A.; Torret, M. and Fondu, P. (1990): Desferrioxamine, improve neutrophil phagocytosis in thalassemia major. Am. J. Haematol; 35 : 13 – 17.

Carraro, M.C.; Rossetti, L.; Gerli, G.C. (2001): Prevalence of retinopathy in patients with anemia or thrombocytopenia. Eur. J. Haematol., 67(4): 238-44.

Cases, A.; Kelly, J.; Sabater, F.; Torras, A.; Grino, M.C.; Lopez-Pedret, J. and Revert, L. (1990): Ocular and auditory toxicity in

hemodialyzed patients receiving desferrioxamine. Nephron., 56(1): 19-23.

Cases, A.; Kelly, J.; Sabater, J.; Campistol, J.M.; Torras, A.; Montoliu, J.; Lopez, I. and Revert, L. (1989): Acute visual and auditory neurotoxicity in patients with end-stage renal disease receiving desferrioxamine. Clin. Nephrol., 32(1): 48.

Cerami, A.; Grady, R.W.; Peterson, C.M. and Bhargava, K.K. (1990): The status of new iron chelators. Ann. Acad. Sci., 344: 425-35.

Chan, Y.L.; Li-Ck; Pang, LM. and Chik, K.W. (2000): Desferrioxarnine-induced long bone changes in thalassemic patients-Radiographic feature, prevalence and relation with growth; clinical Radiography; 55 (8): 610 – 614.

Chang, Y.C.; Smith, K.D.; Moore, R.D.; Sergeant, G.R. and Dover, G.J. (1995): An analysis of fetal hemoglobin variation in sickle cell disease: the relative contribution of the X-linked factor, beta-globin haplotypes, alpha-globin gene number gender and age. Blood, 85(4): 1111-1117.

Charterjee, R. and Katz, M. (2000): Reversible hypogonadotrophic hypogonadism in sexually infantile male thalassemic patients with transfusional iron overload. Clin. Endocronnol., 53(1): 33-42.

Cherchi, G.B.; Pacifico, L.; Cossellu, S.; Gallisai, D.; Zanetti, S.; Fadda, G. and Chiesa, C. (1995): Prospective study of Yersinia enterocolitica infection in thalassemic patients. Pediatr. Infect. Dis. J., 14(7): 579-84.

Chiodo, A.A.; Alberti, P.W.; Sher, G.D.; Francombe, W.H. and Tyler, B. (1997): Desferrioxamine ototoxicity in an adult transfusion-dependent population. J. Otolaryngol., 26(2): 116-22.

Clarke, G.M. and Higgins, T.N. (2000): Laboratory investigation of hemoglobinopathies and thalassemias: review and update. Clin. Chem., 46: 1284-90.

Cohen, A.R. (1987): Management of iron overload in pediatric patient. Haematol. Oncol. Clin. North Am., 521.

Cohen, A.R.; Galanello, R.; Piga, A.; DiPalma, A. and Vullo, C. (2000): Safety profile of the oral iron chelator deferiprone: a multicentre study. Br. J. Haematol., 108: 305-312.

Cohen, A.R.; Martin, M.; Mizanin, J.; Konkle, D.F. and Schwartz, E. (1991): Vision and hearing during deferoxamine therapy. J. Pediatr., 117(2): 326-30.

Cohen, A.R.; Mizanin, J.; Schwartz, E. (1989): Rapid removal of excessive iron with daily high dose intravenous chelation therapy. J. Pediatr., 115: 151-55.

Cohen, A.R.; Renzo-Galanello, Antonio Piga, Vincenzo De Sanctis, Fernando Tricta (2003): Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood; 102(5): 1583-87.

Collins, F.S. and Weissman, S.M. (1984): The molecular genetics of human hemoglobin. Prog. Nucl. Acid. Res. Mol. Biol., 31: 315-462.

Collman, B.H. (2000): In Hall and Collman's Deseases of the nose and Ear 15th edition, Chapter 9: 195.

Covington, T.R.; Dipolma, J.R.; Hussar, D.A.; Lassagna, L.; Tatra, D.S. and Whitsett, T.L. (1985): Antidotes, desferrioxamine mesylate. In: Drug facts and comparisons. JB Lippincott Co., Philadelphia and Tornoto, PP. 1949.

Crain M, Jaswon MS and Chew E. (1994): Management of chronic disease. Eur. J. Pediatr., 155: 326- 329.

Daniel M and Frederick A (2000): Principles and practice of ophthalmology. 6th edition chapter 4: 306-316.

Dattani, M.T. and Preecc, M.A. (1998):Physical growth and development: In Forfar textbook of Pediatrics, Vol. 1, 5th ed., 350: 365.

Davis, B.A. and Porter, J.B. et al. (2000): Long-term outcome of continuous 24-hours deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. Blood, 15, 95(4): 1229-36.

De Andiaca I, Castill OM and Walter T. (1997): Psychomotor development and behavior in iron deficient anemic infants. Nut Rev; 55(4): 125-32.

De Sanctis, V. (2002): Growth and puberty and its management in thalassemia. Horm. Res., 58(1): 72-9.

De Sanctis, V. and Pintor, C. et al. (1995): Multicentre study on endocrine complicationsin thalassemia major. Clinical Endocrinology, 42: 581-6.

De Sanctis, V.; Pinamonti, A. and Di Palma, A. et al. (1996): Growth and development in thalassemia major patients with severe bone lesions due to desferrioxamine. Eur. J. Pediatr., 155: 368-372.

De Swart-Wallace, J.; Eroncy, P. and Finkletein, J. (1999): Iron chelation with deferoxamine: comparing the results of a critical pathway to a national survey. J. Pediatr. Hematol. Oncol., 21(2): 136-141.

De VereJoul, M.C.; Girot, R.; Gueris, J.; Cancela, L.; Bong, S.;Bidakoff, J.M.; Autalen, C.; Goldber, D. and Miravet, L. (1982): Calcium phosphate metabolism and bone disease in patients with homozygous thalassemia. J. Clin. Endocrin. Metabol., 54: 276-81.

De Virgiliis, S.; Argioluf, Sanna, G.; Cornacchia, G.; Cossu, P.; Cao, A.; Mallardi, V. and Puxeddu, P. (1979): Auditory involvement in thalassemia major. Acta. Hematol., 61(4): 209-15.

Dennerlein, J.A.; Lang, G.E.; Stahnke, K.; Kleihauer, E. and Lang, G.K. (1995): Ocular findings in Desferal therapy. Ophthalmologe; 92(1): 38-42.

Diatewa, M.; Makele, C.; Dzila, D.R. and Nzingoula, S. (1995): Icterus and beta-thalassemia in Congolese children in Brazzaville. Arch. Pediatr., 2(3): 287-8.

Dickerhoff, R. (1987): Acute aphasia and loss of vision with desferrioxamine overdose. Am. J. Pediatr. Hematol. Oncol., 9(3): 287-8.

Dimopolou, I.; Kremastinos, D.T.; Maris, G.; Mavrogeni, S. and Tzelepsis, E. (1999): Respiratory function in patients with thalassemia and iron overload. Eur. Respir. J., 13(3): 602-5.

Edward, J.; Benz, Jr. and Patricia, J.V. (1995): Thalassemia syndromes. In: Blood diseases of infancy and childhood textbook, 7th ed., Philadelphia Sydney Tokyo Toronot., 460-491.

El-Ashmawi, S.A.; Abd El-Moneim, A.M.; Zeiwar, M.M. and Mahfouz, M.H. (1985): Study of erythrocyte enzymes in beta thalassemia major. Egypt, J. Hematol., 10(1-2): 73-9.

El-Beshlawy, (2000): Thalassemia in Egypt. Management and prevention prospects. For the 2nd workshop on prenatal diagnosis of thalassemia.

El-Beshlawy, A.; Abdel-Dayen, S. and Abdel-Raouf, E. et al. (2001): Effect of L-carnitine on growth of Egyptian children with thalassemia major. Med. J. Cairo Univ., 69(1): 7-12.

El-Beshlawy, A.; Kaddah, N.; Ragab, L.; Hussein, L. and Hassaballa, N. (1999): Thalassemic prevalence and status in Egypt. Pediatr. Res., 45(5): 102-7.

El-Beshlawy, A.; Ragab, L.; Hussein, I. et al. (1995): Genotypes, phenotypes in Beta thalassemia and sickle cell anemia in Egypt. JAC 6(2): 147-155.

Eldor, A. and Rachmilewitz, E.A. (2002): The hypercoaguable state in thalassemia. Blood; 99(1): 36-43.

Eldor, A.; Durst, R.; Hy-Am, E.; Goldfarb, A.; Gillis, S.; Rachmilewitz, E.A.; Abramov, A.; Maclouf, J.; Goedefrauy, Y.; De Raucourt, E. and Gullin, M.C. (1999): A chronic hypercoagulable state in patients with beta thalassemia major. Br. J. Hematol., 107(4): 739.

El-Gendy, F.; Abou El-Ella, S.; El-Rashidi, F.; Hazza, N. and Ragab, S. (2003): Auditory functions in thalassemic children under desferrioxamine therapy. Minoufia Medical Journal, 16(1): 127-135.

El-Karaksy, H. (1998): Viral hepatitis and B-thalassemia major in children. Second international conference on thalassemia and hemophilia update. Cairo, Egypt.

Elkind D. (1974): Children and adolescents. Interpretative essays on Jean Piaget. New York: Oxford University Press.

Emara, A.; Tawfik, S. and El-Alfy, M. (1992): Effects of desferrioxamine and salicyl hydroxamic acid (SHAM) on hearing in B thalassemia major. Msc. Ain Shams University.

English, D. (1999): Expanding mobilized progenitors for hematotherapy. Journal of Hematotherapy, 8(2): 91-92.

Eranchini, M.; Giardini, G.; De Gironcoli, M.; Vassanelli, A.; Borgna-Piganetti, C. and Aprili, G. (2000): Safety and efficacy of subcutaneous bolus injection of deferioxamine in adult patients with iron overload. Blood, 95(9): 2776-2779.

Filosa, A.; Maio, S.; Esposito, G.; De Matinis, F. and De.Terlizzi, F. (2001): Persistence of delayed adrenarche in boys with thalassemia. J. Pediatr. Endocrinol. Metra., 14(4): 407-14.

Fiorelli, G.; Fargion, S.; Piperrno, A. and Cappellini, M.D. (1990): Iron and thalassemia. Haematologica; 75: 89-95.

Flier, J.S. and Maratos-Flier, E. (1998): Obesity and the hypothalamus: novel peptides for new pathways. Cell, 92: 437.

Fortina, P.; Parrella, T. and Sartore, M. (1994): Interaction of a rare illegitimate recombination event and a poly A addition site mutation resulting in a severe form of alpha thalassemia. Blood, 83: 3356-3362.

Foulds WS (1987): 50th Bowman Lecture "blood is thicker than water". Some haemorheological aspects of ocular disease. Eye 1: 343-363.

Franchini, J.; Boyden, H. and Hrrison, P. (2000): Benefits of chelation therapy in Beta- thalassemia. Semin haematol 33 : 315 - 317.

Freedman, M.H.; Boyden, M.; Taylor, M. and Skarf, B. (1988): Neurotoxicity associated with deferoxamine therapy. Toxicology; 49(2): 283-90.

Frost, H.M. (2001): Seeking genetic causes of "osteoporosis" insights of the Utah paradigm of skeletal physiology. Bone, 29(5): 407-12.

Fuchs, G.J.; Tienboon, P.; Linpisarn, S.; Mimsakul, S.; Leelapat, P.; Tovanabutra, S.; Tubtong, V.; DeWier, A. and Suskind, R.M. (1996): Nutritional factors and thalassemia major. Arch. Dis. Child, 74: 224-7.

Gabutti, V. and Piga, A. (1996): Results of long term chelation therapy. Acta. Haematologica; 95: 26-36.

Gallant, T.; Boyden, M.H.; Gallant, L.A.; Carley, H. and Freedman, M.H. (1989): Serial studies of auditory neurotoxicity in patients receiving deferoxamine therapy. Am. J. Med., 86(3); 365-6.

Gartaganis, S.; Ismiridis, K.; Papageorgiou, O.; Beratis, N.G. and Papanastasiou, D. (1989): Ocular abnormalities in patients with beta thalassemia. Am. J. Ophthalmol., 108(6): 699-703.

Gedikoglu, G. (2001): Bone marrow transplantation in thalassemia. Bone Marrow Transplant., 28(2): 1-10.

Ghaly Isis, et al., (2002): National Growth Charts for Egypt.

Ghareb, A. (1988): Beck depression inventory scale (published by El-Nahda press).

Giani, M.; Hayward, R.A. and Breves, D. (1988): Hearing and desfferrioxamine Haematologica; 72 : 73 – 75.

Giardina, P.J. and Grady RW (1995): Chelation therapy in beta-thalassemia: The benefits and limitations of desferrioxamine. Semin Hematol 32: 304-312.

Gil KM, Williams DA, Thompson RJ and Kiney TR (1991): Sickle cell disease in children and adolescents, the relation of child and parent pain coping strategies to adjustment. Journal of Pediatric Psychology; 16: 643-663.

Goulfd, E.D. (1987): 50th Bowman lecture blood is thicker than water. Some haemorheological aspects of ocular disease. Eye, 1: 343-363.

Gresveld, F.; Van Assendelft, G.B.; Breaves, D.R. et al. (1987): Position-independent, high level expression of the human B-globin gene in ransgenic mice. Cell, 51: 975-85.

Grupp, S.A. (1997): Hematologic disorders, manual of pediatric theraputies, 6th edition, Lippincott-Raven. 55 – 75.

Guidelines for the Clinical Management of thalassaemia. TIF. (2000): 25 – 26.

Gutton, A.C. and Hall, J.E. (2000): In: Textbook of medical physiology, 10th edition, Gutton, A.C. and Hall, J.E. (eds) W.B. Saunders Company, Philadelphia, London, Chapter 51: 652.

Hahalis, G.; Manolis, A.S.; Gerasimidou, I.; Alexopoulos, D. and Sitafidis, G. (2001): Right ventricular diastolic function in beta-thalassemia major: Echocardiographic and clinical correlates: American Heart Journal; 14(3): 428-434.

Harrison, P.M. (1997): Ferritin: an iron storage molecule. Semin. Hematol., 214: 55.

Hassan, M.Y. (2001): Thalassemia. Medicine, J., 2(11): 1-42.

Hattori, Y. (1999): Diagnosis and therapy of hemoglobinopathies. Nippon Naika Gakkai Zasshi, 88(6): 1010-5.

Hay, W.W.; Groothuis, R.J.; Hayward, R.A. and Levin, J.M. (2001): Current pediatric diagnosis and treatment in 14th ed. Chapter 4: 123-126.

Hayward, C.; Killen, J.; Wilson, D. and Hammer, L. (1997): Psychiatric risk associated with early puberty in adolescent, Journal of American Academy of Child & Adolescent Psychiatry, 36(2): 255-262.

Herman-Giddens, M.E.; Slora, E.J. and Wasserman, R.C. et al. (1997): Secondary sexual characteristics and menses in young girls seen in office practice: a study from the pediatric research in office settings network. Pediatrics, 99: 501-12.

Ho, P.J.; Hall, G.W. and Luo, L.Y. et al. (1998): Beta thalassemia intermedia is it possible consistently to predict phenotype from genotype. Br. J. Haematol., 100: 70-8.

Hoffmam, N.; Gary, M. and Dellaconte, G. (1995): Desfferrioxamine therapy. Journal of Haemtotherapy; (3) : 29 – 92.

Hoing, G.R. Adams, J.G. (2004): Hemolytic Anemias. In "Nelson, Textbook of pediatric" 17th ed. Beh WE and Vaughan rman,

RE, Gliegman RM, Nelson VC (eds) Saunders Co. Philadelphia, London, Toronto 1245 : 1256.

Huisman, T.H.J.; Carver, M.F.H.; Baysal, E. (1997): A syllabus of thalassemia mutations. Augusta: The sickle cell anemia foundation 150 – 153.

Hurtado E.K.; Claussen, A.H. and Scott K.G. (1999): Early childhood anemia and mild or moderate mental retardation. Am J Clin Nutr; Jan 69(1): 115-9.

Hussein, I.R.; El-Beshlawy, A. and Temtomy, S. et al. (2000): Prevention of B-thalassemia in Egypt By Carrier Detection and Prenatal Diagnosis, For the 2nd Workshop on Prenatal Diagnosis of Thalassemia.

Hussein, J. (1999): Helping a child with chronic illness. M.S.C Thesis in Pediatrics Benha Faculty of Medicine. 86-87.

Ibrahim, B.; Sallam, S. and El-Tawila, S. (2000): Transitions to adulthood a national suruary of Egyptian adolescents, 2nd ed., 32: 42.

Ikuta, T.; Atweh, G.; Boosalis, V.; White, G.L.; Da-Fonseca, S.; Boosalis, M.; Faller, D.V. and Perrine, S.P. (1998): Cellular and molecular effects of a pulse butyrate regimen and new inducers of globin gene expression and hematopoesis. Ann. NY Acad. Sci., 6(30): 850-87-99.

Incorvaia, C.; Parmeggiani, F.; Costagliola, C.; Perri, P.; D'Angelo, S. and Sebastiani, A. (2003): Quantitative evaluation of the retinal venous tortuosity in chronic anemic patients affected by beta-thalassemia major. Eye; 17(3): 324-9.

Ishak, S.; Sarkis, M. and Kaddah, N. (1990): Growth and sexual maturation in Egyptian thalassemic patients; Bulletin of Egypt. Soc. Physiol. Sci., 10(4).

James, M. and Perrin, P. (2004): Impact of chronic illness. In: Nelson textbook of pediatrics. 17th edition. Behrman, RE, Gliegman RM RE, Gliegman RM, Nelson VC (eds) Saunders Co Philadelphia, London, Toronto chapter 17: 121-124.

James, P.; Kushner, John, P. Porter, and Olivieri, N.F. (2001): Secondary Iron Overload. Hematology, (1) : 47 – 61.

Kaplinsky, C.; Stark, B.; Goshen, Y.; Yaniv, I.; Bashara, S. and Zaizov, R. (1988): Deferoxamine induced ocular toxicity. Pediatr. Hematol. Oncol., 5(4): 293-7.

Karimi, M.; Asadi, A.A.; Khademi, B. and Asadi, K. (2002): Evaluation of the incidence of sensorineual hearing loss in B thalassemia patients under regular chelation therapy with DFO. Acta. Haematol., 108: 79-83.

Katzos, G.; Haroulis, F.; Papadopoulou, M.; Athanasiou, M. and Sava, K. (1995): Circadian Growth hormone secretion in short multitransfused prepubertal children with thalassemia major. European J. Pediatr., 154: 445-449.

Katzos, G.; Papakostantinou-Althanasiadau, E. Althanasiou-Metaea, M. and Marsoulis, F. (2000): Growth hormone treatment in short children with beta-thalassemia major. J. Pediatr. Endocrinol. Metab., 13(2): 163-70.

Kazazian, H.H. (1990): The thalassemia syndromes: molecular basis and prenatal diagnosis. Semin. Hematol., 27: 209.

Kendall AG (1993): Thalasssemias. J Med; I: 1169-73.

Khojasteh, N.H.; Zakernia, M.; Ramzi, M. and Haghshenas, M. (2002): Bone marrow transplantation for hematological disorders-Shiraz experience. Indian J. Pediatr., 69(1): 31-32.

Klagsbrun M, Soker SVEGF/VPF (1994): The angiogenesis factor found? Curr Biol 3: 699-702.

Klerman, G.L. (1980): Depression disorder in : Comperhensive textbook of psychiatry 3rd ed. Vol. 11, PP. 902-19, Baltimore: the Williamsnad Wilkins Co.

Kontzoglou, G.; Koussi, A.; Tsatra, J.; Noussios, G.; Vital, V.; Sagarakis, G. and Athanassiou, M. (1996): Sensorineural hearing loss in children with thalassemia major in Northern Greece. Int. J. Pediatr. Otorhinolaryngol., 35(3): 223-30.

Kushner, J.P.; John, P. Porter, and Olivieri, N.F. (2001): Secondary iron overload. Hematology, (1): 47-61.

Ladis, V.; Berdousi, H.; Palamidou, F.; Agrafioti, C.; Papadopoulou, A.; Anagnostopoulos, G.; Theodorides, C.; Kattamis, C. (2000): Morbidity and mortality of iron intoxication in adult

patients with thalassemia major and effectiveness of chelation. Transfusion- Science; 23(3): 255-256.

Lang GE, Spraul CW and Lang GK (1998): Ocular manifestation of hematological diseases. Klin Monatsbl Augenheilk 212: 419-427.

Lanzkowsky, M.B. (2000): Hemolytic anemia. In: Manual of Pediatric Hematology and Oncology, 3rd (ed.) Academic Press, PP. 137-200.

Lattanzi, F.; Bellotti, P.; Picano, E.; Chiarella, F.; Mazzarisi, A.; Melevendi, C. and Forni, G. (1993): Quantitative ultrasonic analysis of myocardium in patients with thalassemia major and iron overload. Circulation, 93; 87(3): 748-54.

Lee K (1995): Fatal intracranial hemorrhage in two cases of beta thalassemia major. Med J Malaysia; 50(1): 110-3.

Lena Russo, D.; Erny, N.; Serradimigni, F. and Badens, C. et al. (1996): Genetic hemoglobin diseases. Prevention at centers for family planning and education of maternal-child protection in Marseille. Press Med., 25(4): 141-3.

Leukens, J.N. (1993): The thalassemias and related disorders. In: Wintrobes Clinical Hematology, 9th edition, Lee, G.R., Bithell, T.C.; Forester, J.; Athens, J.W. and Lukens, J.N. (eds). Philadelphia, USA 312 – 315.

Li, C.K.; Chik, K.W.; Lam, C.W.K.; To, K.F.; Yu, S.Ch.; Lee, V.; Shing, M.M.K. and Cheung, A.Y.K. (2002): Liver disease in transfusion dependent thalassemia major. Arch. Dis. Child, 86: 344-347.

Lih, I.F. (1995): Pubertal and psychological development: implications for pediatricians. Pediatr. Rev., 16: 243.

Loewenstein, J.I. (1995): Retinopathy associated with blood anomalies. In: Jakobieck F, ed. Clinical Ophthalmology. Revised edn. Philadelphia: JB Lippincott Company 3(85): 955-1000.

Longueville, A. and Chichton, R.R. (1986): Iron chelation therapy. Biochem. Pharmacol., 36: 3669-78.

Louthrenoo, O.; Siltipreechacharn, S; Thanrattanakor, P. and Sanguansermsri, T. (2004): Psychological problems in children with B thalassemia. Med Assoc Thai., 85(8): 881-5.

Low, C.K.; Kwan, Y.W.; Cheung, P.T.; Li, M.C.; Ha, S.Y.; Lau, Y.L. and Karlberg, J. (1998): Short stature in beta-thalassemia. Chin. Med. J., 111(8): 731-5.

Low,C.K.; Kwan, Y.W.; Cheung, P.T.; Li, M.C.; Ha, Sy.Y.; Lau, Y.L. and Karlberg, J. (1998): Short stature in beta-thalassemia. Chin. Med. J. 111 (8): 731 – 5.

Lucarelli, G.; Andreani, M. and Angelucci, E. (2002): The cure of thalassemia by bone marrow transplantation. Blood Rev., 16(2): 81-5.

Lucarelli, G.; Clift, R.A.; Galimberti, M.; Angelucci, E. and Giadini, C. et al. (1999): Bone marrow transplantation in adult thalassemic patients. Blood, 93(4): 1164-1167.

Lucarelli, G.; Giardini, C. and Angelucci, E. (1997): Bone marrow transplantation in thalassemia cancer. Treat. Res., 77: 305-15.

Lukens, J.N. (1993): The thalassemia and related disorders. In: Wintrobes Clinical Hematology, 9th ed. Edited by Lee GR, Bithell TC., Foerster J., Athens JW., Lukens JN. Lea and Febiger, Philadelphia, 1102-32.

Mahmoud, H.K. (1999): Allogenic and autologous stem cell transplantation. 10 yrs experience in a developing country. ASCO Panarab meeting.

Mahmoud, H.K.; Fahmy, O.A. and Kamel, A. et al. (1999): Peripheral blood vs bone marrow as a source for allogenic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 24: 355-358.

Malik, P. (2003): Toward gene therapy for B-thalassemia: new models, new approaches. Blood, 101(8): 2902-2903.

Masala W, Meloni F, Gallisai D, Careddu M, Secchi G, Cuccuru GB, Loriga V and Salvo G. (1988): Can deferroxiamine be considered an ototoxic drug? Scand Audiol Suppl 30: 237-238.

Massaglia P. and Caprignano M. (1987): Psychology of the thalassaemic patient and his family. In G. Sirchia and A. Zanella (eds.), Thalassaemia today the Mediterranean experience (pp. 141-145). Milano: T.O.M.P.

Massala, A.; Melan, T.; Gallisai, D.; Alagna, S.; Rovasio, P.P.; Rassu, S. and Melia, A.F. (1984): Endocrine functioning in multitransfused prepubertal patients with homozygous beta thalassemia. J. Clin. Endocrinol. Metab., 58: 667-670.

McDonagh, K.T. and Neinhuis, A.W. (1998): The thalassemia. In: Hematology of infancy and childhood 5th ed., Nathan DG. And Oski FA., (eds) WB Saunders Company, Philadelphia; 858-859.

Michelson, J.; Cohen, A. (1998): Incidence and treatment of fractures in thalassemia. J. Orthop Trauna. 2 : 29.

Mikelli, A. and Tsiantis, J. (2004): Depressive symptoms and quality of life in adolescence with beta thalassemia. Journal of Adloscence, 27: 212-216.

Monge, L.; Pinach, S.; Caramellino, L.; Berfero, M.T.; Dalpono, A. and Carta, W. (2001): The possible role of autoimmunity in the pathogenesis of diabetes in B-thalassemia major. Diabetes Metab., 27(2): Pt 1: 149-154.

Muretto, P.; Angelucci, E. and Lucarelli, G. (2002): Reversibility of cirrhosis in patients occurred in thalassemia by bone marrow transplantation. Ann. Intern. Med., 136(9): 67-72.

Nathan, D.G. and Orkin, S.H. (1998): Hematology of infancy and childhood the thalassemia. W.B. Saunders Company. 85 – 87.

Nathan, D.G.; Piomilli, S. (1990): Introduction: Oral iron Chelators. Semin. Hematol., 27: 83.

Needlman, R.D. (2004): Growth and development. In: Nelson textbook of Pediatric, Chapter 14, 53:57.

Nelson W, Vaughan V. and McKay J. (1996): The Anemia in Nelson text book of pediatric 3rd volume.. Philadelphia, Pennsylvania WP Saunders Co chapter452 ,1514-15.

Nienhuis, A.W. and Henry, W. (1977): Evaluation and treatment of chronic iron overload. In: Zanio EC, Roberts RH (eds): Chelation therapy in chronic iron overload. Miami, Symposium Specialists, Inc., P1.

Northern, J.L. and Downs, M.P. (2002): Hearing and hearing loss in children. In: Northern JL and Downs, M.P. (Eds) Hearing in children. Lippincott Williams and Wilkins, P. : 1- 31.

Oliveri, N. (1999): Medical Progress. The beta-thalassemias. New England Journal of Medicine, 341(2): 99-109.

Olivieri, N.F. and Brittenham, G.M. (1997): Iron-chelating therapy and the treatment of thalassemia. Blood, 89: 739-761 (Erratum, Blood, 89: 2621-7).

Olivieri, N.F. and Weatherall, D.J. (1999): Thalassemias in pediatric hematology textbook 2nd ed. London, Edinburgh, New York, Philadelphia, Sydney Toronto., 307-327.

Olivieri, N.F.; Briuenham, G.M. and McLaren, C.E. et al. (1998): Long-term safety and effectiveness of iron-chelation therapy with deferiprone in patients with thalassemia major. N. Engl. J. Med., 339: 417-23.

Olivieri, N.F.; Buncic, J.R.; Chew, E.; Gallant, T.; Harrison, R.V.; Kennan, N.; Logan, W.; Mitchell, D.; Ricci, G. and Skarf, B. et al. (1986): Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. N. Engl. J. Med., 314(14): 869-73.

Olivieri, N.F.; Gary, M. and Brittenham, N.J.(1997): Iron-Chelating therapy and the treatment of thalassemia. Blood; 89(3): 739-61.

Olivieri, N.F.; Koren, G. and Harris, J. et al. (1992): Growth failure and bony changes induced by deferoxamine. Am. J. Pediatr. Hematol. Oncol., 14: 48-56.

Orkin, S.H. and Nathan, D.G. (1998): The thalassemias in hematology of infancy and childhood by Nathan DG and Orkin SH (eds), 811-888, SAUNDERS.

Pall, H.; Blake, D. and Winyard, P. (1989): Ocular toxicity of desferrioxamine, an example of copper promoted auto-oxidative damage. Br. J. Ophthalmol., 73: 42-47.

Pallister, C. and Rotstein, O.D. (2001): Yersinia enterocolitica as a cause of intra-abdominal abscess: the role of iron. Can. J. Surg., 44(2): 135-6.

Papanastasiou D, Paanacoliou D, Magakiou A, Beratis N, Tzeblakos E and Papapetroquolos T. (1991): Peripheral neuropathy in patients with beta thalassemia. J Neurol Neurosurg and Psychiatry; 45 (11): 979-1000.

Pearson, H.A.; Cohen, A.R.; Giardini, P.J.V. and Kazarian, H.H. (1996): The changing profile of homozygous B thalassemia demography ethnicity and age distribution of current north-American patients and changes in two decades. Pediatrics, 97: 352-356.

Perrin, J.M. (2004):Developmental disabilities and chronic illness: In Nelson textbook of Pediatric, Chapter 37, 135: 37.

Perrin, J.M. Pearson, H.A. and Haris, J. (1994): Health care reform and special needs of children. Pediatrics, 93(3): 504-506.

Persons, D.A.; Hargrove, P.W.; Allay, E.R.; Hanawa, H.; Neinhuis, A.W. (2003): The degree of phenotypic correction of murine Beta-thalassemia following lenti viral-mediated transfer of a human-globin gene is influenced by chromosomal position effects and vector copy number. Blood, 101(6): 21765-2183.

Peter, L.; Greenberg, Victor Gordeuk, Surapol Issaragrisii, Noppadol Siritanaratkul, Suthat Fucharoen, Raul C. and Ribeiro (2001): Major hematologic diseases in the developing world: New Aspects of diagnosis and management of thalssemia, Malarial Anemia and acute leukemia. Hematology, (5): 97-105.

Piatti, G.L.; Allegra, U.; Ambrosetti, et al. (1999): Beta-thalassemia and pulmonary function. Haematologica, 84(9): 804-8.

Plant, T.M.; Lee, P.A. eds. (1995): The Neurobiology of puberty. Bristol: Society for Endocrinology. Proceedings of the latest (4^{th}) international conference on the control of the onset of

puberty, containing summaries of current theories of physiology control, as well as GnRH analog treatment.

Popescu, C.; Siganos, D.; Zanakis, E. and Padakis, A. (1998): The mechanism of cataract formation in persons with beta-thalassemia. Oftalmologia; 45(4): 10-3.

Porter JB, Jaswon MS, Huehns ER, East CA and Hazell JW (1989): Deferrioxamine ototoxicity: Evaluation of risk factors in thalassaemic patients and guidelines for safe dosage. Br J Haematol 73: 403-409.

Porter, J.; Davis, B. and Weir, T. et al., (2001): Preliminary findings with single-dose evaluation of a new depot formulation of deferoxamine (ICL 449B) for transfusion-dependent beta-thalassemia. Florida, The Saratoga Group, Ponte Verde Beach.

Porter, J.B.; Alberti, D.; Huehns, E.R. et al. (1997): Subcutaneous depot desferrioxamine (CGH 749B) relationship of pharmacokinetics to efficacy and drug metabolism. Blood, 90; Suppl. 1: 265 abstract.

Porter, J.B.; Fatherty, A.; Stallibrass, L.; Brookman, L.; Hassan, I. and Howes, C. (1998): A trial to investigate the relationship between DFO pharmacokinetics and metabolism and DFO-related toxicity. Annals of the New York Academy of Sciences; 850: 483-87.

Porter, J.B.; Jaswon, M.S.; Huehns, E.R.; East, C.A. and Hazell, J.W. (1989): Desferrioxamine ototoxicity: evaluation of risk factors in thalassemic patients and guidelines for safe dosage. Br. J. Haematol., 73(3): 403-9.

Porter, J.B.;Albenti, D. and Hazell, J.W. (1999): Respiratory complications of β thalassemia. Brj. Haematol. Oncol, 89; 48 : 55.

Protonotariou, A.A. and Tolis, G.J. (2000): Reproductive health in female patients with beta thalassemia major. Ann. N.Y. Acarel. Sci., 900119-24.

Quirollo, K. and Vichinsky, E. (2004):Chronic haemolytic anemia, Nelson textbook of pediatrics, 17 edition Philadelphia, Pennsylvania WP Saunders Co. Ch. 454, 1630: 34,

Rachmilewitz, E.A. and Aker, M. (1998): The role of recombinant human erythropoietin in the treatment of thalassemia. Ann. N.Y. Acad. Sci., 6(30): 850: 120-138.

Ragab, L. (2000): Management protocol for the treatment of thalassemia patients. Second workshop on prenatal diagnosis of thalassemia, Cairo, Egypt.

Ramos-Remus, C. and Galvan-Villegas, F. (2001): A hair-on-end skull. N. Engl. J. Med., 345.

Rasekhi, A.R.; Bagheri, M.H.; Sadergholvaad, A.S. (2000): Correlation between pituitary MRI and hypogandotropic hypogonadism in β thalassemia.

Ravelli, M.; Scaroni, P.; Mombelloni, S.; Movilli, E.; Feller, P.; Apostoli, P.; De Maria, G.; Valotti, C.; Sciuto, G. and Maiorca, R. (1990): Acute visual disorders in patients on regular dialysis given desferrioxamine as a test. Nephrol. Dial. Transplant., 5(11): 945-9.

Raymond, J.; Bergeron, Jan Wiegand, Gary, M. and Brittenham (1998): HBED: A potential alternative to deferoxamine for iron-chelating therapy. Blood; 91(4): 1446-52.

Rinadilin, Della, Corten, Ruoccov; Donotrioc, Zanotta, G. and Raman (1993): Occulor involvement correlated with age in patients affected by major and intermedia – Beta- thalassemia treated or not with desferrioxamine-Metab pediat. Syst. Ophthalmol; 16 (1-2) 23 – 5.

Rinaldi, M.; Della, Corte, M.; Ruocco, V.; D'Onofrio, C. and Zanotta, G.; Romano. (1993): Ocular involvement correlated with age in patients affected by major and intermedia beta-thalassemia treated or not with desferrioxamine. Metab Pediatr Syst. Ophthalmol; 16 (1-2) : 23 – 5.

Robert .J and Joyant, M. (1992): Neurological complications of internal diseases. Clinical Neurology. Vol. 4, Chap (58) Mcgraw-Hill Tnc.

Robert, J. and Joyant, M. (1998): Neurological complications of internal diseases. Clinical Neurology. Vol. 4, Chap (58) Mcgraw-Hill Tnc.

Robert ,H. R.Dickerhof ,C. and Barr, J et al(2002);Reversibility of DFO toxisty on eye J. Pediatr Ophthalmol;25(4)115-118

Rodda, C.P. (1994): Body proportions in patients with homozygous B-thalassemia. Acta. Pediat., 406: 107-108.

Romcal, D.; Tositarat, T. and Ulapongs, P. (1988): Activitjes of liver cell producing coagulation factors in thalassemic children. Birth Defects; 23(58): 237-43.

Rosina, P.; D'Onghia, F.S.; Chieregato, C.; V;asanell, A. and Bertuzzo, D. (2001): Leg ulcers and hemoglobinopathies. Acta. Pediat., 136(3): 195-201.

Sacco, M.; Meleleo, D.; Tricarico, N.; Greco Miani, A.; Serra, E. and Parlatore, L. (1994): Evaluation of desferrioxamine ototoxicity in thalassemic patients. Follow-up over a 5-year period and results. Minerva Pediatr., 46(5): 225-30.

Sadowski, H.; Tsiantis, J.; and Kolvin, I. et al., (2002): Psychopathology in children from families with blood disorders: A cross-national study. Europena Journal Child Adolescent Psychiatry, 11(4): 151- 161.

Sakhuja, S.(2004)Education for all and learning disabilities in India,SSPC,NewDelhi

Saleh, A. (1989): The picture intelligence test for children (published by El-Nahda press).

Sartoiro, A.; Conti, G.; Conh, A.; Masula, A.; Alagna, S.; Rovasio, P. and Faglia, G. (2000): Effects 12 month rec-GH therapy on bone and collagen turnover and bone mineral density in GH deficient children with thalassemia major. J. Endocrinol. Invest., 23(6): 356-61.

Schowalter, J.E. (1983): Psychology of physical illness during adolescence. Psychosomatics; 24: 453-461.

Sedalain, M.; Frassoni, F. and Riviere, I. (2000): Issues in the manufacture and transplantation of genetically modified hematopoetic stem cells. Curr. Opin. Hematol., 364-377.

Senanayake, M.P.; Surawera, S.A.; Hubert, H.D. (2004): Thyroid function in thalassemia major. Ceylon Med. J., 44(4): 166-8.

Shahar, A. and Sadeh, M. (1991): Severe anemia associated with transient neurological deficits. Stroke; 22(9): 1201-2.

Shebl, S. and Wael, F. (2000): A comparative study of neuropsychiatric aspects in children with iron deficiency anemia and cooly's anemia.

Shebl, S.S.; Abo Hussin, S.; Shoheib, S. and Fatma, M.Ch. (1992): Pancreatic function in children with B thalassemia before and after iron chelation herapy. In: International Mediterranean conference on endocrine disorders in thalassemia. Cosenza, Italy, PP. 70.

Shebl, S.S.; El-Sharkawy, H.M. and El-Fadaly, N.H. (1999): Haemostatic disorders in non-splenectomised and splenectomised children. Easter Mediterranean Health Journal, 5(6).

Shebl, S.S.; Shoheib, S.; El-Fadali, N. and Abo-Raya, Z.A. (1994): Red cell enzymes and electrolytes in children with B thalassemia before and after chelation therapy. In: The first international summer symposium on tropical hematology. Palastine Hotel. Alex. Egypt, 24-26.

Sheikha A, Kameswaran M.; Okafor B.C. and Al-Saigh A.A. (1992): Otological manifestations of thalassaemia intermedia: Evidence of temporal bone involvement and report of a unique cholesteatoma-like lesion. J Laryngol Otol 106: 316-321.

Shepperd, L.; Hoffibrand, A.; Bartlett, A. and Barr, J. (1990): 1-Ethyl-2-methyl-3- hydroxypyrid 4-one (LINET). A new orally effective iron chelator for the treatment of transfusional iron overload in man. An abstract submitted from Blood supplement of 32nd Annual meeting of American Society Hematology; 255.

Sherman M, Koch D, Giardina P, Hymowitz P, Siepel R and Shapiro T (1985): Thalassaemic children's understanding of illness: A study of cognitive and emotional factors. Annals of the New York Academy of Science; 445: 326-327.

Simon, P.; Ang, K.; Meyrier, A.; Allain, P. and Mauras, Y. (1983):jDesferrioxamine, Ocular toxicity and trace metals. Lancet; 11 : 512 – 13.

Singer, S.T.; Wu, V.; Mignacca, R.; Kuyper, F.A. and Morel, P. (2000): Immunological reactions in beta thalassemia .Blood, 96(10): 3369-3373.

Sklar, C.A.; Lew, L.Q. and Yoon, D.J. et al. (1987a): Adrenal function in the thalassemia major following long-term treatment with multiple transfusion and chelation therapy. Evidence for dissociation of cortisol and adrenal androgen secretion. Am. J. Dis. Child, 141: 237.

Sklar, C.A.; Lew, L.Q.; Yoon, D.J. and David, R. (1987): Adrenal function in thalassemia major following term treatment with multiple transfusion and chelation therapy. Evidence for dissociation of cortisol and adrenal androgen secretion. Am. J. Dis. Child, 141: 327-333.

Soliman, A.; El-Zalabany, M.M.; Amera, M. and Ansari, B.M. (1999): Growth and pubertal development in transfusion dependant children and adolescents with thalassemia major and sickle cell diseases A comparative study. Trop. Pediat., 45: 23-30.

Soliman, A.T.; El-Zalabany, M.M.; Mazloum, Y.; Bedair, S.M.; Ragab, M.S.; Rogol, A.D. and Ansan, B.M. (1999a): J. Trop. Pediatr., 45(6): 327-37.

Soliman, T. (2000): Bone mineral density in pre pubertal children with beta thalassemia: correlation with growth and hormonal data. TIF. Nes. No. (31): 1920.

Sorcienlli, R.; Sitzia, A.; Figus, A. and Lai, M.E. (1990): Ocular findings in beta-thalassemia. Metab Pediatr Syst Ophthalmol; 13 (1): 23 – 5.

Sorcinelli, R.; Sitzia, A.; Figus, A. and Lai, M.E. (1990): Ocular findings in beta-thalassemia. Metab. Pediatr. Syst. Ophthalmol., 13(1): 23-5.

Spirito, A.; Stark L.; Gil K. and Tyk V. (1995): Coping with everyday and related stressors by chronically ill children and adolescents. Journal of the American Academy of Adolescent Psychiatry; 34: 3.

Spitz, I.M. and Hirsch, H.J. (1984): TSH secretion in thalassemia major. J. Endocrinol. Invest., 7: 495-501.

Triantafyllou, N.; Fisfis, M.; Sideris, G.; Triantafyllou, D.; Rombos, A.; Vrettou, H.; Mantouvalos, V.; Politi, C.; Malliara, S. and Papageorgiou, C. (1991): Neurophysiological and neuro-otological study of homozygous beta-thalassemia under long-term desferrioxamine (DFO) treatment. Acta. Neurol. Scand., 83(5): 306-308.

Tsiantis I (1990): Family reactions and relationships in thalassaemia. Annals of the New York Academy of Science; 612: 451-461.

Tsiantis, I. (1984): Psychiatric disorders and interlligence of children with thalassaemia. Thesis, Medical School, University of Athens, Greece (in Greek). 51 – 63.

Valenti, S.; Giusti, M.; McGuinness, D.; Guido, R.; Mori, P.G.; Giordano, G.; Dahl, K.D. (1995): Delayed puberty in males with B-thalassemia major: pulsatile gonadotropin-releasing hormone administration induced changes in gonadotropin isoform profiles and an increase in sex steroids. Eur. J. Endocr., 133: 48-56.

Verna P, Duri P (1998): Ischemic retinitis as a result of acute episodic blood loss. Int Ophthalmol 22: 331-333.

Vetter, B.; NEU-Yilik, G.; Kohne, E.; Arnold, R.; Gaedicke, G.; Ivaceviev, V. and Kulozik, A.E. (2000): Dominant B-thalassemia highly unstable hemoglobin is caused by a novel 6bp deletion of the B-globin gene. Br. J. Hematol., 108: 176-181.

Voskarido, E.; Kyrtsonis, M.C.; Terpos, E.; Skorchili, M. and Theocloropoulos, I. (2000): Bone resorption is increased in young adults with thalassemia major. British Journal of Hematology, 112(1): 35-41.

Vullo, C.; De Santis, V. and Katz, M. (1990): Endocrine abnormalities in thalassemia. Ann. NY Acad. Sci., 612: 293-310.

Walsh, T. and Devlin, M. (1998): Eating disorders: Progress and problems. Science, 280: 1387-1390.

Weatherall, D.J. (2001): The thalassemias. In: The molecular basis of blood diseases. Stamatuyannopoulos G, Nienhuis AW, Majerus PH, Varmus H, eds. 3rd ed. Philadelphia: WB Saunders, 183-220.

Weatherall, D.J. and Clegg, G.B. (1995): The thalassemia syndrome (6th ed.). Oxford, UK, Blackewell Scientific Publisher, 344-60.

Weatherall, D.J. and Clegg, J.B. (1996): Thalassemia a global public health problem. Nat. Med., 2: 847-849.

Weatherall, D.J. and Clegg, J.B. (2001): The thalassemia syndromes. Oxford: Blackwell Science 724 – 729.

Weatherall, D.J.; Clegg, J.B. and Higgs, D.R. et al. (1994): The hemoglobinopathies in the metabolic basis of inherited diseases. Edited by Seriver, C.R., Beauder, A.L.; Sly, W.S. and Valle, D., McGrow-Hill, New York 407 – 417.

Weatherall, D.J.; Clegg, J.B.; Higgs, D.R. and Wood, W.G. (1995): The hemoglobinopathies. In: Scriver CR, Beaudet AL, Sly WS, Valle D. (eds): the metabolic basis of inherited disease, 7th ed. New York McGraw-Hill Book Co., 3417-3484.

Wetherall, D.J. (1999): Genetic disorders of haemoglobin. In: Hoffrand A.V., Lewis S.M. and Tuddenham, E.G.D. (eds) Postgraduate haematology, 4th ed. Butterwerth Heinemann, Ch. 6, P. 91-118.

Wonke, B.; Hoffbrand, A.V.; Aldouri, M.; Wickens, D.; Flynn, D.; Stearns, M. and Warner, P. (1989): Reversal of desferrioxamine induced auditory neurotoxicity during treatment with Ca-DPTA. Arch. Dis. Child., 64(1): 77-82.

Yaish, H.M. (2001): Thalassemia at www.emedicine.com.

Youssef, S. (1998): Adverse effects of transfusion therapy. Second international conference on thalassemia and hemophilia update. Cairo, Egypt.

Zamboni, G.; Marradi, P.; Taglliaro, F.; Dorizii, R. and Tai, O.L. (1986): Parathyroid hormone, calcitonin and vitamin D metabolites in B thalassemia major. Eur. J. Pediatr., 145(1): 133-6.

Zani B, Di Palma and Vullo C (1995): Psychosocial aspects of chronic illness with thalassaemia major. Journal of adolescence; 18: 387-402.

group 1	age	sex	order in family	residence (U-R)	mother level of education	father ocupation	degree of consanguinity	number of sibs affected	number of sibs died with thala	family dysfunction	age of diagnosis (yr)	age of first transfusion (yr)	age of start desferal (year ago	frequency of transfusion even	Hb pre-transfusion gm%
1	13	M	6	U	secondary	manual	no	1	0	no	1.5	1.5	7	2w	7.5
2	9.5	M	1	R	primary	professional	no	1	0	no	1.5	2	3.5	3w	7.1
3	14	F	1	U	high	civilian	1st	2	0	no	1.5	2	5	3w	6.8
4	17	F	2	U	high	civilian	no	1	0	no	2.5	3	4	2w	7.3
5	10	F	2	R	primary	civilian	1st	2	0	no	1	1	5	4w	6.5
6	12	F	2	U	primary	manual	no	1	0	family breaks	0.5	0.5	3	2w	7.3
7	12	F	1	U	secondary	market	1st	2	0	no	0.5	0.5	9	2w	6.4
8	10	M	2	U	primary	civilian	1st	2	0	no	0.5	0.5	6	2w	6.6
9	13	M	2	R	illiterate	market	no	1	0	no	1.5	1.5	2.5	2w	6.9
10	15	M	4	U	secondary	civilian	no	2	1	no	1	1	10	2w	7.1
11	12	M	3	U	illiterate	manual	2nd	1	0	no	0.5	0.5	4	4w	6.8
12	18	F	2	R	illiterate	manual	no	2	0	no	1	1.5	8	3w	7.2
13	14.5	M	2	R	secondary	manual	1st	1	0	no	2	2	5	2w	6.7
14	10	F	2	R	primary	civilian	2nd	2	0	no	1.5	1.5	3	3w	7.1
15	9	M	6	R	secondary	market	2nd	2	0	no	1	1.5	4	4w	6.9
16	11	M	3	R	illiterate	civilian	1st	2	0	no	2	2.5	5	2w	7.9
17	15.5	M	1	R	illiterate	manual	1st	2	1	family breaks	2	2.5	5	3w	6.8
18	13	F	2	R	illiterate	civilian	1st	3	1	family breaks	2	2	3	4w	6.4
19	14.5	M	2	R	secondary	unempolyed	1st	1	0	no	2	2	5	2w	6.9
20	11	M	3	R	illiterate	market	1st	2	0	no	1.5	2	5	3w	7.9
21	12	F	2	U	primary	civilian	no	1	0	family breaks	0.5	0.5	3	2w	7.2
22	10	M	2	U	secondary	manual	1st	2	0	no	1	1	6	2w	6.4
23	15.5	M	1	R	illiterate	mauanl	1st	2	1	no	2	2.5	5	2w	6.7
24	9	M	4	R	illiterate	civilian	no	1	0	no	2.5	2.5	2	2w	7.2
25	11	M	1	R	primary	mauanl	no	2	0	no	0.5	0.5	9	2w	6.8
26	11	M	1	R	illiterate	civilian	distant	1	0	no	2	2.5	3	4w	6.3
27	14	F	3	U	high	civilian	distant	1	0	no	1.5	2	4	2w	7.1
28	13	F	2	R	primary	market	1st	3	1	family breaks	2	2	5	2w	6.9
29	16	M	4	R	illiterate	market	1st	1	0	family breaks	2.5	2.5	6	3w	6.7
30	10	F	3	R	illiterate	unempolyed	1st	3	1	no	0.5	1	2	2w	7

group 1	helation therapy in last 6 month	frequency of chelation/week	dose of chelating drug (mg/kg	ferritin level (last 3 mo) ng/dl	H/o ear inf. Pain, bldg	H/o of operation	insulin for DM	thyroxine for Hypoth	weight for age per kg	weight centile	height for age per cm	height centile	sitting height in cm
1	pump	5	50	600	no	minor	no	no	30	below 3rd	134	below 3rd	68
2	pump	5	45	740	no	splenectomy	no	no	26	10-25th	128	10th	79
3	pump	5	30	750	no	no	no	no	44	10-25th	150	10th	80.5
4	pump	5	40	625	no	splenectomy	no	no	49	10-25th	149	3rd	69
5	pump	5	50	765	no	splenectomy	no	no	20	below 3rd	115	below 3rd	56
6	pump	5	33	970	no	no	no	no	29.5	below 3rd	146	25th	76
7	pump	5	30	670	no	minor	no	no	37	10-25th	140	10th	76.5
8	pump	5	25	1040	no	no	no	no	30	25th	136	25-50th	71
9	pump	5	20	890	no	splenectomy	no	no	31.5	below 3rd	140	5th	85
10	pump	5	28	900	no	splenectomy	no	no	40.5	3rd	147	below 3rd	74
11	pump	5	32	660	no	splenectomy	no	no	34	3rd	135	5th	82.5
12	pump	5	20	960	no	splenectomy	no	no	51	50-75th	150	25th	80
13	pump	5	42	1030	no	minor	no	no	40	5th	150	3-5th	70.5
14	pump	5	20	970	no	no	no	no	31	25-50th	133	25th	80
15	pump	5	32	860	no	no	no	no	26	25th	125	10th	75
16	pump	5	42	660	no	no	no	no	34	25th	137	25th	85
17	pump	5	28	970	no	splenectomy	no	no	34	below 3rd	142	below 3rd	65
18	pump	5	40	890	no	splenectomy	no	no	29	below 3rd	127	below 3rd	58
19	pump	5	42	1030	no	minor	no	no	40	5th	150	5th	70.5
20	pump	5	40	660	no	no	no	no	34.5	25th	137	25th	85
21	pump	5	34	860	no	no	no	no	29.5	below 3rd	146	25th	86
22	pump	5	25	1040	no	no	no	no	30	25th	136	25-50th	73
23	pump	5	29	960	no	splenectomy	no	no	33.5	below 3rd	142	below 3rd	65
24	pump	5	24	870	no	no	no	no	22	5th	125	10th	80
25	pump	5	30	670	no	no	no	no	33	25th	138	25th	85
26	pump	5	21	930	no	no	no	no	33	25th	131	5th	83
27	pump	5	40	1100	no	no	no	no	51.5	50th	160	50th	85
28	pump	5	50	890	no	splenectomy	no	no	29	below 3rd	127	below 3rd	68
29	pump	5	25	1050	no	splenectomy	no	no	30	below 3rd	135	below 3rd	71
30	pump	5	45	1090	no	splenectomy	no	no	27	10th	129	3rd	58

centile for Sht	BMI	centile for BMI	MAC in cm	biacromial diameter in cm	Bi-ischial diameter in cm	stage of Genitalia	stage of public hair	age of menarche	age of first ejaculation	spleen span below costal mar	liver span in cm	bone deformity/fractures	IQ	depression scale results	* pure tone audimetry	visual * acuity	visual * field	visual * fundus ex	school performance
below 3rd	16.7	10-25th	19	27	23	SMR2	SMR2	no	no	6cm	11	mongloid F	95	mild	HFSND	6/9 - 6/12	normal	normal	poor
below 3rd	15.8	25th	18.5	26	22	SMR2	SMR2	no	no	4 cm	10.5	mongloid F	100	no	normal	normal	normal	normal	average
25th	19.5	25-50th	21	33	24.5	SMR2	SMR2	no	no	4cm	15	mongloid F	100	no	normal	normal	PFD	normal	average
10-25th	22	25-50th	24	23.5	29	SMR3	SMR4	no	no	ectomy	14	mongloid F	86	moderate	HFSND	normal	normal	normal	poor
below 3rd	15.1	10-25th	17	24.5	22	SMR2	SMR1	no	no	ectomy	14	mongloid F	94	no	normal	normal	PFD	normal	average
below 3rd	13.8	below 3rd	18	29	24.5	SMR2	SMR3	no	no	5cm	10	mongloid F	95	moderate	normal	6/12 - 6/18	normal	normal	poor
10th	18.8	25-50th	19	27	25	SMR3	SMR3	no	no	5cm	12	mongloid F	105	no	HFSND	6/12 - 6/9	PFD	opt. Cupping	average
10-25th	16.2	below 3rd	16	29	23	SMR2	SMR2	no	no	4cm	11.5	mongloid F	98	no	normal	normal	normal	normal	average
25th	16.1	5-10th	16	27.5	23.5	SMR2	SMR2	no	no	ectomy	13	mongloid F	102	no	normal	normal	normal	normal	average
50th	16.1	below 3rd	17.5	30	24	SMR3	SMR4	no	14	ectomy	13.5	mongloid F	105	mild	HFSND	normal	normal	normal	average
below 3rd	18.3	25-50th	19	30.5	23	SMR2	SMR2	no	no	ectomy	11.5	mongloid F	100	mild	normal	6/9 - 6/9	normal	normal	average
25th	22.6	50-75th	20	36	30	SMR3	SMR3	14.5	no	ectomy	14	mongloid F	95	mild	HFSND	normal	PFD	normal	average
10th	17.7	10-25th	19	31	23.5	SMR2	SMR2	no	no	7cm	16	mongloid F	108	mild	normal	normal	normal	normal	average
5th	17.5	50th	18	25	23	SMR2	SMR2	no	no	4cm	12.5	mongloid F	100	mild	normal	normal	normal	normal	average
25th	16.6	25-50th	16	27	20.5	SMR1	SMR1	no	no	7cm	11.5	mongloid F	98	no	normal	normal	PFD	normal	average
5th	18.1	50th	18.5	30.5	24.5	SMR2	SMR1	no	no	6cm	12	mongloid F	94	mild	HFSND	normal	PFD	normal	average
10-25th	16.9	3-5th	16.9	30	25	SMR3	SMR3	no	14	ectomy	13.5	mongloid F	98	mild	HFSND	normal	normal	normal	average
below 3rd	17.9	25th	17.9	26	20	SMR2	SMR1	14	no	ectomy	11	mongloid F	102	mild	normal	normal	normal	normal	average
below 3rd	17.7	10-25th	17.7	30.5	23.5	SMR2	SMR3	no	14.5	5cm	15	mongloid F	108	no	normal	normal	normal	normal	average
3rd	18.1	50th	18.1	30.5	24.5	SMR2	SMR1	no	no	6cm	12	mongloid F	94	no	HFSND	normal	normal	normal	average
10th	13.8	below 3rd	13.8	29	24	SMR2	SMR3	no	no	5cm	10	mongloid F	85	moderate	normal	6/9 - 6/12	PFD	normal	poor
10-25th	16.2	25-50th	16.2	29	23	SMR2	SMR2	no	no	4cm	11.5	mongloid F	98	no	normal	normal	PFD	normal	average
below 3rd	16.9	3-5th	17.5	30	25	SMR2	SMR3	no	14	ectomy	13.5	mongloid F	95	mild	HFSND	6/12 - 6/12	normal	normal	average
10th	14.1	5th	16	22	20	SMR1	SMR1	no	no	3.5cm	10.5	mongloid F	105	no	normal	normal	PFD	normal	average
10-25th	17.3	25-50th	17	28.5	23	SMR1	SMR2	no	no	5cm	11.5	mongloid F	100	mild	HFSND	6/9 - 6/9	PFD	normal	average
5th	19.2	50-75th	20	30	23	SMR3	SMR2	no	no	4cm	1.5	mongloid F	87	mild	normal	normal	PFD	normal	poor
25th	19.8	50th	23.5	32	29	SMR3	SMR4	14.5	no	4cm	13.5	mongloid F	98	no	normal	normal	PFD	normal	average
below 3rd	17.9	25th	16.5	26	20	SMR2	SMR1	no	no	ectomy	11	mongloid F	102	mild	HFSND	6/12 - 6/12	normal	opt. Cupping	average
below 3rd	16.3	below 3rd	18	29	23.5	SMR2	SMR3	no	no	ectomy	14	mongloid F	80	mild	normal	normal	normal	normal	poor
3rd	17.5	50th	16.5	26.5	22.5	SMR2	SMR2	no	no	ectomy	11	mongloid F	108	no	normal	normal	normal	normal	average

group 2	age	sex	order in family	residence (U-R)	mother level of education	father occupation	degree of consanguinity	number of sibs affected	number of sibs died with thal	family dysfunction	age of diagnosis (yr)	age of first transfusion (yr)	age of start desferal (year ag	frequency of transfusion	Hb pre-transfusion gm%
1	12	F	1	U	illitrate	manual	1st	2	1	family breaks	1.5	2	3	3w	6.9
2	10	M	2	R	secondary	unemployed	no	1	0	no	1.5	1.5	4	2w	7.4
3	15	M	1	R	illitrate	professional	distant	1	0	no	3	3	0	2w	7.8
4	14.5	M	2	U	illitrate	civilian	2nd	1	0	no	1.5	2	4	4w	7.5
5	18	F	3	R	illitrate	manual	1st	2	0	family breaks	1	1	3	2w	6.7
6	14	M	4	U	secondary	market	1st	1	0	no	2	2.5	4	4w	7.2
7	14	F	6	R	illitrate	manual	1st	1	0	family breaks	2	2.5	6	2w	7.5
8	16	F	1	R	secondary	manual	1st	2	0	no	1.5	1.5	0	6w	7.3
9	14.5	M	1	U	secondary	civilian	no	2	0	family breaks	3	3.5	6	2w	7.8
10	14	F	4	U	illitrate	market	2nd	3	1	family breaks	3.5	3.5	0	2w	8.4
11	15	M	1	R	high	civilian	1st	1	0	no	2.5	2.5	5	3w	8
12	14	M	1	R	illitrate	civilian	no	2	0	no	3	3	6	4w	8.2
13	18	F	3	U	primary	manual	no	2	0	family breaks	1	1	3	2w	7.2
14	15	F	1	R	primary	civilian	1st	1	0	no	2	2	0	4w	7.3
15	15	F	1	R	illitrate	civilian	1st	1	0	no	2	2	0	2w	7.2
16	17	F	3	U	illitrate	civilian	no	2	1	family breaks	1.5	2.3	5	3w	7
17	10	F	2	R	high	market	no	1	0	no	1.5	1.5	4	3w	6.9
18	15	F	2	U	illitrate	market	1st	3	1	no	2	2	0	2w	8
19	17	F	3	R	primary	civilian	no	2	0	no	1.5	1.5	5	3w	7.8
20	18	M	2	R	primary	civilian	2nd	2	0	family breaks	1	1.5	3	4w	7.9
21	16	M	3	R	illitrate	civilian	1st	2	0	no	2	2	7	3w	8
22	17	M	1	R	primary	civilian	no	1	0	family breaks	2.5	2.5	4	2w	8.3
23	13	M	7	R	illitrate	market	no	1	0	family breaks	1.5	2	2	3w	7.6
24	15	M	2	R	primary	unemployed	1st	3	0	family breaks	0.5	0.5	3	4w	7.3
25	11	F	3	R	primary	market	1st	3	0	family breaks	2	2	2	3w	8
26	18	F	2	R	primary	unemployed	no	2	0	no	1	1.5	8	4w	7.1
27	13	F	2	U	primary	unemployed	2nd	1	0	no	1.5	1.5	6	4w	6.9
28	9.5	M	6	R	primary	manual	2nd	2	0	divorce	1	1.5	0	4w	7.4
29	10.5	M	1	U	illitrate	professional	no	1	0	no	1.5	1.5	3	4w	7
30	11	M	5	R	primary	manual	2nd	1	0	no	2	2	2	2w	6.9

group 2	elation therapy in last 6 mont	frequency of chelation/week	dose of chelating drug (mg/k	ferritin level (last 3 mo) ng/dl	H/o ear inf. Pain, bldg	H/o of operation	insulin for DM	thyroxine for Hypoth	weight for age per kg	weight centile	height for age per cm	height centile	sitting height in cm
1	IV	0.5	17	2300	no	splenectomy	no	no	30.5	3rd	134	below 3rd	65
2	IV	0.5	20	1800	no	no	no	no	26.5	10th	140	below 3rd	56
3	none	0	0	3200	no	splenectomy	no	no	40	below 3rd	134	below 3rd	65
4	pump	3	45	1000	no	no	no	no	36	below 3rd	146	below 3rd	68.5
5	none	0	0	4700	no	splenectomy	no	no	48	5-10th	148	below 3rd	64
6	pump	1	20	1300	no	minor	no	no	27	below 3rd	144	3rd	65
7	pump	2	25	1450	no	splenectomy	no	no	39	10-25th	136	below 3rd	65
8	none	0	0	2600	no	splenectomy	no	no	35	below 3rd	134	below 3rd	62
9	none	0	0	2000	no	splenectomy	no	no	37	below 3rd	146.5	below 3rd	67
10	none	0	0	2300	no	splenectomy	no	no	44	10-25th	146	3-5th	87
11	pump	2	35	1103	no	no	no	no	42	5th	154	5th	84
12	pump	1	50	1200	no	splenectomy	no	no	33	below 3rd	136	below 3rd	77
13	pump	3	20	1800	no	splenectomy	no	no	49	10th	146	below 3rd	67
14	none	0	0	3200	no	minor	no	no	41	5th	140	below 3rd	69
15	none	0	0	3200	no	minor	no	no	41	5th	140	below 3rd	69
16	IV	0.5	27	1750	no	splenectomy	no	no	36	below 3rd	130	below 3rd	60.5
17	pump	2	30	1200	no	no	no	no	23.5	3rd	124	3rd	55
18	none	0	0	3200	no	splenectomy	no	no	39	3rd	138	below 3rd	67
19	IV	3	20	2600	no	splenectomy	no	no	37	below 3rd	132	below 3rd	61.5
20	pump	1	40	1300	no	no	no	no	51	3rd	148	below 3rd	74
21	none	0	0	2300	no	splenectomy	no	no	38	below 3rd	131	below 3rd	67
22	IV	0.5	25	1550	no	splenectomy	no	no	48	3rd	140	below 3rd	73
23	pump	3	15	2200	no	no	no	no	32	below 3rd	115	below 3rd	63
24	none	0	0	2700	no	splenectomy	no	no	26.5	below 3rd	126	5th	81
25	IV	0.5	25	2100	no	splenectomy	no	no	19	below 3rd	116	below 3rd	58
26	pump	3	20	1800	no	splenectomy	no	no	49	10th	146	below 3rd	67
27	IV	0.5	12	1900	no	no	no	no	42	below 3rd	140	below 3rd	63
28	none	0	0	2300	no	no	no	no	29	25-50th	117	below 3rd	61
29	none	0	0	2100	no	minor	no	no	28	10-25th	123	below 3rd	64
30	pump	3	18	1800	no	no	no	no	32	10-25th	134	10th	84

centile for SHt	BMI	centile for BMI	MAC in cm	biacromial diameter in cm	Bi-ischial diameter in cm	stage of Genitalia	stage of public hair	age of menarche	age of first ejaculation	spleen span below costal m	liver span in cm	bone deformity/fractures	IQ	depression scale results	* pure tone audimetry	visual * acuity	visual * field	visual * fundus ex	school performance
below 3rd	16.9	25th	17	28	24	SMR1	SMR2	no	no	ectomy	13	mongloid F	85	mild	normal	normal	normal	normal	poor
below 3rd	17.2	50th	16.5	24	20.5	SMR1	SMR1	no	no	4 cm	10.5	mongloid F	92	no	normal	normal	normal	normal	average
below 3rd	22.3	50-75th	21	30	24	SMR2	SMR2	no	no	ectomy	15	mongloid F	95	moderate	normal	normal	normal	normal	poor
below 3rd	16.9	5-10th	19.5	31	23.5	SMR3	SMR2	no	14	7cm	10	mongloid F	94	mild	normal	6/9 - 6/12	normal	normal	average
below 3rd	21.9	25-50th	24	27	28	SMR2	SMR3	no	no	ectomy	16	mongloid F	92	moderate	normal	normal	normal	normal	poor
below 3rd	13	below 3rd	16	27	20	SMR2	SMR2	no	no	4cm	14.5	mongloid F	94	mild	normal	normal	normal	normal	average
below 3rd	21.1	50th	20.5	31	26	SMR3	SMR2	no	no	ectomy	14.5	mongloid F	92	mild	normal	normal	normal	normal	average
below 3rd	18.1	5-10th	20	29	25	SMR3	SMR2	15	no	ectomy	14	mongloid F	84	moderate	normal	normal	normal	normal	poor
below 3rd	17.4	10-25th	19.5	31.5	23	SMR2	SMR2	no	no	ectomy	13	mongloid F	80	mild	normal	normal	normal	normal	poor
10th	20.6	25-50th	22	29	27	SMR2	SMR2	no	no	ectomy	12	mongloid F	90	mild	normal	normal	normal	normal	poor
below 3rd	17.7	10-25th	22.5	32	25	SMR2	SMR3	no	no	5cm	15	mongloid F	99	no	normal	normal	normal	normal	average
below 3rd	17.8	10-25th	20.5	28	22	SMR2	SMR2	no	no	ectomy	13	mongloid F	105	mild	normal	normal	normal	normal	average
below 3rd	22.1	25-50th	19	35	29	SMR3	SMR2	15.5	no	ectomy	16	mongloid F	82	moderate	normal	normal	normal	normal	poor
below 3rd	20.9	25-50th	21	31	27	SMR2	SMR2	no	no	7cm	13.5	mongloid F	86	moderate	normal	normal	normal	normal	poor
below 3rd	20.9	25-50th	21	31	27	SMR2	SMR2	no	no	7cm	13	mongloid F	86	moderate	normal	normal	normal	normal	poor
below 3rd	21.3	25-50th	16	24	26	SMR2	SMR3	no	no	ectomy	12	mongloid F	90	moderate	normal	normal	normal	normal	poor
below 3rd	15.3	10-25th	15	24.5	18.5	SMR2	SMR1	no	no	5cm	14	mongloid F	92	no	normal	normal	normal	normal	average
below 3rd	20.5	25-50th	20.5	30.5	26	SMR2	SMR3	14	no	ectomy	15	mongloid F	92	moderate	normal	normal	normal	normal	poor
below 3rd	21.2	25-50th	18	25	27	SMR3	SMR2	15.5	16	5cm	14	mongloid F	80	mild	normal	normal	normal	normal	poor
below 3rd	23.2	50-75th	21.5	33	25	SMR2	SMR2	no	no	ectomy	15.5	mongloid F	94	moderate	normal	normal	normal	normal	average
below 3rd	22.1	50-75th	20.5	30	23.5	SMR2	SMR2	no	no	ectomy	14.5	mongloid F	90	moderate	normal	normal	normal	normal	poor
below 3rd	24.4	75th	21	32	25	SMR2	SMR4	no	16.5	ectomy	14.5	mongloid F	92	mild	normal	normal	normal	normal	average
below 3rd	17.5	50th	17.5	29	24.5	SMR1	SMR1	no	no	6cm	15	mongloid F	86	mild	normal	normal	normal	normal	poor
5th	16.6	5th	16	27.5	23	SMR2	SMR2	no	no	ectomy	16	mongloid F	94	mild	normal	normal	normal	normal	poor
below 3rd	14.1	below 3rd	14	20	20.5	SMR2	SMR1	no	no	ectomy	12	mongloid F	98	mild	normal	normal	normal	normal	average
below 3rd	22.1	25-50th	19	35	29	SMR3	SMR2	15	no	ectomy	14	mongloid F	82	mild	normal	normal	normal	normal	poor
below 3rd	21.4	25th	19.5	31	28	SMR2	SMR2	no	no	4cm	13	mongloid F	80	no	normal	normal	normal	normal	poor
below 3rd	21.2	85th	18	28	21	SMR1	SMR1	no	no	8cm	11	mongloid F	85	moderate	normal	normal	normal	normal	poor
below 3rd	18.5	50-75th	17.5	27.5	21	SMR1	SMR1	no	no	4cm	12	mongloid F	92	no	normal	normal	normal	normal	average
10th	17.8	50-75th	20.5	32	23.5	SMR1	SMR2	no	no	8cm	12	mongloid F	88	no	normal	normal	normal	normal	poor

control group	age	sex	order in family	residence (U-R)	mother level of education	father ocupation	family dysfunction	IQ	depression scale results	school performance
1	10	M	2	U	secondary	civilian	no	99	no	average
2	12	M	3	U	high	civilian	no	100	no	average
3	9	F	1	R	illiterate	manual	divorce	84	mild	poor
4	18	F	6	U	primary	market	no	105	no	average
5	17	F	4	R	primary	manual	no	98	no	average
6	14	F	1	R	illiterate	civilian	no	102	no	average
7	13	M	1	R	illiterate	market	no	99	no	average
8	9	M	1	R	high	manual	no	108	no	average
9	11	F	2	R	illiterate	market	no	110	no	average
10	15	M	3	R	primary	unempolyed	no	105	no	average
11	10	M	3	U	primary	civilian	no	100	no	average
12	11	F	2	R	primary	market	no	95	no	average
13	17	F	6	U	secondary	professional	no	90	no	average
14	16	F	5	R	illiterate	civilian	no	94	no	average
15	16	M	1	R	illiterate	manual	no	95	no	average
16	10	M	6	U	secondary	civilian	no	110	no	average
17	11	F	6	U	secondary	civilian	no	105	no	average
18	9	F	3	R	primary	manual	no	95	no	average
19	15	M	4	R	secondary	market	no	100	no	average
20	12	F	2	U	primary	market	no	108	no	average